A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Srđan Verstovšek(Unknown), Josef T. Prchal(Huntsman Cancer Institute), Richard A. Walgren(Eli Lilly (United States)), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Celine Pitou(Eli Lilly (United States)), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Fabio P. Nunes(Eli Lilly (United States)), Li Li(Army Medical University), Gregory L. Price(Eli Lilly (United States)), Deborah N. D’Souza(Syneos Health (United States)), Jennifer L K Giles(Eli Lilly (United States))
Cited by 41
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cancer incidence and mortality in China, 2016
|Journal of the National Cancer Center|2022|1.6k
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|619
Spectrum of Epithelial Neoplasms in End-Stage Renal Disease
|The American Journal of Surgical Pathology|2006|484